IFF and SleepScore Labs to Unveil Validated Scent Solutions to Support Improved Sleep at CES 2022
IFF (NYSE: IFF) and SleepScore Labs introduce a groundbreaking scent solution to improve sleep quality, building on the partnership initiated in 2020 and leveraging IFF’s internal Science of Wellness program. The two companies will be demonstrating the new solution at the CES 2022 in Las Vegas - a scent that showed sleep improvement on an objective level in a SleepScore Labs study, including faster time to fall asleep, less time spent awake during the night, longer sleep duration, and improved sleep efficiency.
“IFF has always been a pioneer when it comes to creating scent solutions to improve people’s lives”, says Christophe de Villeplée, IFF’s Scent Division President. “The two first years of our partnership with SleepScore Labs were used by our perfumers and innovation teams to develop scents using our data science and SleepScore Labs biometric measures to improve sleep quality. The CES show will allow tech savvy visitors to discover our unique scent wellness solution and experience it firsthand”.
With 70% of the developed world impacted by poor sleep and the resulting adverse effects on overall health, the need to develop data-driven solutions is a call to action. IFF, an industry leader in food, beverage, scent, health and biosciences, and SleepScore Labs, the company behind a comprehensive suite of data-backed sleep solutions, leverage their combined expertise with a science-based, biometrically measured scent solution to support improved sleep.
The two organizations have collaborated to produce in-context biometrically tested scents. The studies utilize SleepScore’s non-contact measurement technology to extract respiratory signal and body movements, to not only determine sleep-wake cycles but also specific sleep stages, including Light, Deep, and REM. Their technology has been validated using polysomnography (PSG), the gold standard for objective sleep measurement.
”Billions of people are constantly searching for solutions to help them sleep better but most consumer solutions have little or no hard scientific data on their performance,” said Colin Lawlor, CEO of SleepScore Labs. “We are tremendously proud to work with IFF in leveraging the best data and science to bring real products which can be easily used in homes around the world to help people truly sleep better. Duly tested.”
To learn more about the IFF and SleepScore Labs scent sleep solutions, please see the companies’ video, IFFxSleepScore.
Welcome to IFF
At IFF (NYSE: IFF), an industry leader in food, beverage, scent, health and biosciences, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet.Learn more at iff.com, Twitter, Facebook, Instagram, and LinkedIn.
About SleepScore Labs
We’re the sleep science and improvement company changing the world by improving sleep, based on science and leading-edge technology. SleepScore Labs was founded in 2016 by a team of sleep experts from companies, institutions and organizations such as ResMed, Apple, Philips, and Harvard. Together, we enable leading companies and organizations to strengthen their health and wellness offerings, proven through better sleep. After studying over 85 million hours of sleep for over a decade, we created the world’s most comprehensive suite of services which help consumers improve their sleep and companies to improve their offerings in the space
© 2021 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved.
iff.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220102005018/en/
Contact information
IFF
Michael DeVeau
Chief Investor Relations & Communications Officer
212.708.7164
Michael.DeVeau@iff.com
SleepScore Labs
Tracy Frommelt
Tracy.frommelt@sleepscorelabs.com
858-437-9060
About Business Wire
Business WireSubscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Global CIOs geared up to scale AI but organizations aren’t as ready25.4.2024 05:00:00 CEST | Press release
AI is the CIO’s top priority, according to findings of Lenovo’s third annual global CIO report. Inside the Tornado: How AI is Reshaping Corporate IT Today, reveals that while CIOs need to adopt and scale AI urgently, their ambitions are threatened by speed, security, and other organizational functions lagging in AI readiness. In a stark contrast to previous years, CIOs are tabling non-traditional responsibilities to sharpen their focus on core IT functions. Slightly more than half (51%) of CIOs feel AI/ML is an urgent priority to address, matched only by cybersecurity. This urgency is directly correlated to the pressure that CIOs are under to drive business impact, rather than operational maintenance and preservation. 84% of CIOs revealed they are being evaluated on business outcome metrics more than ever before. “Today’s CIOs are working in a tornado of innovation. After years of IT expanding into non-traditional responsibilities, we’re now seeing how AI is forcing CIOs back to their
Mundipharma acquires all assets and rights related to REZZAYO ® (rezafungin) , reinforcing continued commitment to management of infectious diseases and specialty care therapeutic area24.4.2024 22:01:00 CEST | Press release
Mundipharma* today announced the acquisition of all assets and rights related to rezafungin globally from Cidara Therapeutics. This provides Mundipharma with global ownership of rezafungin including ongoing development and distribution. Rezafunginis a novel once-weekly echinocandin indicated for the treatment of invasive candidiasis in adults.1 Invasive candidiasis, is a severe, life-threatening infection of the bloodstream and/or deep/visceral tissues.2,3 It affects seriously ill people, especially those with a weakened immune systemand the mortality rate can be 40%4 or more.5,6 It can place a large burden on the healthcare system, with the potential for extended treatment regimens and long hospital stays.6 Over the last 15 years, there have been no new treatments and morbidity and mortality rates remain largely the same, indicating the need for alternative treatment options.7,8 “This acquisition places Mundipharma in the best position to realise the full potential of rezafungin inclu
Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting24.4.2024 22:01:00 CEST | Press release
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share research outcomes from its broad hematology and solid tumor portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31 - June 4, 2024. “Our presentations at this year’s ASCO highlight the strength of our growing oncology portfolio and our commitment to developing treatments that address the unmet needs of patients with B-cell malignancies and solid tumors,” Mehrdad Mobasher, M.D., M.P.H., Chief Medical Officer, Hematology at BeiGene. “The exciting data we will share during ASCO showcase BRUKINSA’s uniquely differentiated clinical profile and add to the growing body of evidence supporting its role across the blood cancer treatment paradigm.” BeiGene will share new data for BRUKINSA (zanubrutinib), which add to the robust efficacy and safety evidence differentiating it within the BTK class. Key highlights include: A network meta-analysis co
TSMC Celebrates 30 th North America Technology Symposium with Innovations Powering AI with Silicon Leadership24.4.2024 21:30:00 CEST | Press release
TSMC (TWSE: 2330, NYSE: TSM) today unveiled its newest semiconductor process, advanced packaging, and 3D IC technologies for powering the next generation of AI innovations with silicon leadership at the Company’s 2024 North America Technology Symposium. TSMC debuted the TSMC A16TM technology, featuring leading nanosheet transistors with innovative backside power rail solution for production in 2026, bringing greatly improved logic density and performance. TSMC also introduced its System-on-Wafer (TSMC-SoW™) technology, an innovative solution to bring revolutionary performance to the wafer level in addressing the future AI requirements for hyperscaler datacenters. This year marks the 30th anniversary of TSMC’s North America Technology Symposium, and more than 2,000 attended the event, growing from less than 100 attendees 30 years ago. The North America Technology Symposium in Santa Clara, California kicks off TSMC Technology Symposiums around the world in the coming months. The symposiu
Rimini Street Appoints Steve Hershkowitz as Chief Revenue Officer24.4.2024 18:50:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, products, and services, the leading third-party support provider for Oracle and SAP software, and a Salesforce and AWS partner, today announced the appointment of Steve Hershkowitz as its new Chief Revenue Officer (CRO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240424061249/en/ Rimini Street Appoints Steve Hershkowitz as Chief Revenue Officer (Photo: Business Wire) “Steve’s leadership and extensive experience scaling businesses to deliver top-line growth will expand our sales reach to capture new logos and increase our opportunity to provide even greater value to our clients,” said Rimini Street president and CEO Seth Ravin. “The global revenue team and I are excited to work closely together with Steve to drive growth and broader capabilities for our company.” Leading the Next Chapter of Sales Growth and Continued Success f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom